[Clinical trial of the effects of isodibut on several indicators of microcirculation in combined therapy of patients with diabetes mellitus].

Abstract

The authors have tried a new drug isodibut, aldoreductase inhibitor, of Russian produce in 53 patients with diabetes mellitus. A course of isodibut++ has improved blood coagulation and fibrinolysis, microcirculatory blood flow, normalized muscular blood flow as indicated by electrocoagulation, conjunctival biomicroscopy, radionuclide tracing. The drug is recommended for treatment and prevention of diabetic angiopathy.

• Authors: I M Kakhnovskiĭ, T V Koroleva, G A Golubiatnikova, M A Kalinkina
• Journal: Klinicheskaia meditsina (Klin Med (Mosk)) Vol. 74 Issue 3 Pg. 56-8 ( 1996) ISSN: 0023-2149 [Print] Russia (Federation)
• Vernacular Title: Klinicheskaia otsenka vliianiia izodibuta na nekotorye pokazateli mikrotsirkuliatsii v kompleksnom terapii bol'nykh sakharnym diabetom.
• PMID: 8926708 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)

Chemical References

• Enzyme Inhibitors
• Hypoglycemic Agents
• Isoquinolines
• isodibut
• Aldehyde Reductase

Topics

• Adult
• Aged
• Aldehyde Reductase (antagonists & inhibitors)
• Blood Coagulation (drug effects)
• Conjunctiva (blood supply)
• Diabetes Mellitus (drug therapy, physiopathology)
• Diabetes Mellitus, Type 1 (drug therapy, physiopathology)
• Diabetes Mellitus, Type 2 (drug therapy, physiopathology)
• Diabetic Angiopathies (prevention & control)
• Enzyme Inhibitors (administration & dosage, pharmacology, therapeutic use)
• Female
• Humans
• Hypoglycemic Agents (administration & dosage, pharmacology, therapeutic use)
• Isoquinolines (administration & dosage, pharmacology, therapeutic use)
• Male
• Microcirculation (drug effects)
• Middle Aged
• Muscles (blood supply)